Questions Answered on ART Safety and Tolerability in Aging Patients and Populations With Cardiometabolic Toxicities
In this episode, Marta Boffito, MD, PhD, FRCP, and Jens D. Lundgren, MD, DMSc, address key considerations when evaluating antiretroviral therapy safety and tolerability in aging patients and those wit...
17 Tammi 202323min
Emerging Insights on Outpatient Management of Acute COVID-19 and Long COVID in Europe
In this episode, Jens D. Lundgren, MD, DMSc, and Barbara Rath, MD, PhD, HDR, discuss emerging insights on outpatient management of acute COVID-19 and long COVID in Europe, including:Current COVID-19 v...
13 Tammi 202340min
Administration of LA ART by Community Nurses in France
In this episode, Laurence Slama, MD, PhD, describes some of the ways that her clinic is attempting to make IM injections of long-acting antiretroviral therapy more sustainable long term. She explains ...
5 Tammi 20238min
Optimizing PrEP Selection and Persistence for MSM
In this episode, Jason E. Farley, PhD, MPH, ANP-BC, FAAN, FAANP, AACRN, discusses optimizing HIV pre-exposure prophylaxis (PrEP) selection and persistence for men who have sex with men (MSM), includin...
5 Tammi 202319min
PrEP Considerations for Transgender and Nonbinary Individuals
In this episode, Jill Blumenthal, MD, MAS, discusses HIV pre-exposure prophylaxis (PrEP) considerations for transgender and nonbinary individuals, including:Providing gender-affirming careIntegrating ...
5 Tammi 202317min
What Strategies Are Most Promising for Prevention and Treatment of Long COVID in Nonhospitalized Patients?
Fernando Carnavali, MD; Rasika Karnik, MS, MD; and Renslow Sherer, MD, discuss long COVID, including:Long COVID prevention strategies, including COVID-19 vaccinationLong COVID treatment approachesStra...
4 Tammi 20235min
Should We Be Concerned About Resistance and Development of New Variants With COVID-19 Antiviral Therapy?
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 treatments and the possibility for antiviral resistance, including:Treatment resi...
4 Tammi 20237min
Should We Be Concerned About Viral Rebound With Antiviral Agents?
Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss COVID-19 rebound, including:Prevalence of COVID-19 reboundCOVID-19 rebound and antiviral u...
30 Joulu 20224min
